[February 05, 2016]

Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/bn87qr/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview
3. Therapeutics Development
4. Pipeline Products fr Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview
5. Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis
6. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies
7. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
8. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies
13. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes
14. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development

• A. Menarini Industrie Farmaceutiche Riunite Srl
• AB Science SA
• AbbVie Inc.
• Adamis Pharmaceuticals Corporation
• Advaxis, Inc.
• Aeterna Zentaris Inc.
• Alethia Biotherapeutics Inc.
• Ambrx, Inc.
• Amgen Inc.
• AnGes MG, Inc.
• Angion Biomedica Corp.
• Aphios Corporation
• Armour Therapeutics Inc.
• Arno Therapeutics, Inc.
• Arrowhead Research Corporation
• Astellas Pharma Inc.
• Astex Pharmaceuticals, Inc.
• AstraZeneca Plc
• ATLAB Pharma SAS (News - Alert)
• Bavarian Nordic A/S
• Bayer AG
• Beta Pharma, Inc.
• BIND Therapeutics, Inc.
• Bio-Cancer Treatment International Limited
• Biscayne Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CellCentric Ltd
• Celldex Therapeutics, Inc.
• Corcept Therapeutics Incorporated
• CureVac GmbH
• CytoVac A/S
• DexTech Medical AB
• Eisai Co., Ltd.
• Eli Lilly and Company

For more information visit http://www.researchandmarkets.com/research/bn87qr/hormone

View source version on businesswire.com: http://www.businesswire.com/news/home/20160205005801/en/

[ Back To TMCnet.com's Homepage ]